Fenwick & West advised Royalty Pharma on the deal. Royalty Pharma (Nasdaq: RPRX), a buyer of biopharmaceutical royalties and funder of innovation across the biopharmaceutical industry,...
You must be a Standard 1 Year member to access this content.
Davis Polk advised Royalty Pharma plc on the transaction. Royalty Pharma executed its offering of $1.3 billion aggregate principal amount of senior notes. The offering consisted of...
You must be a Standard 1 Year member to access this content.
Wachtell, Lipton, Rosen & Katz and Willkie Farr & Gallagher advised Constellation on the deal. Goodwin Procter, Dechert and Maiwald acted as legal advisors to Royalty...
You must be a Standard 1 Year member to access this content.
Dechert advised Royalty Pharma on the deal. Royalty Pharma plc executed its acquisition of a royalty interest in the cabozantinib products Cabometyx and Cometriq from GlaxoSmithKline...
You must be a Standard 1 Year member to access this content.
